Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth

Cancer Research

Volumn 63, Issue 5, 2003, Pages 1020-1024

  Mendoza, Nerissa ^a   Fong, Sharon ^a   Marsters, Jim ^a   Koeppen, Hartmut ^a   Schwall, Ralph ^a   Wickramasinghe, Dineli ^a,b  

^a GENENTECH INC   (United States)

^b Department of Molecular Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLIN A; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; PEPTIDE DERIVATIVE; PROLYLVALYLLYSYLARGINYLARGINYLLEUCYLASPARTYLLEUCINE; PROLYLVALYLLYSYLARGINYLARGINYLLEUCYLPHENYLALANYLGLYCINE; PROLYLVALYLLYSYLARGINYLARGINYLLEUCYLPHENYLALANYLLEUCINE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE CONTROL; GENE INACTIVATION; GENE REPRESSION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR CELL; TUMOR MODEL; TUMOR SUPPRESSOR GENE;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CDC2-CDC28 KINASES; CELL DIVISION; CELL LINE, TRANSFORMED; CYCLIN A; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; CYCLINS; FEMALE; GENES, ERBB-2; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; PROTEIN-SERINE-THREONINE KINASES; RATS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION;

EID: 0037374549     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Knudsen, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA, 68: 820-823, 1971.
2. Strauss, M., Lukas, J., and Bartek, J. Unrestricted cell cycling and cancer. Nat. Med., 1: 1245-1246, 1995.
3. Hall, M., and Peters, G. Genetic alterations of Cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res., 68: 67-108, 1996.
4. Malumbres, M., and Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer, 13: 222-231, 2001.
5. Sherr, C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996.
6. Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev., 12: 2245-2262, 1998.
7. Dynlacht, B. D., Flores, O., Lees, J. A., and Harlow, E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev., 8: 1772-1786, 1994.
8. Krek, W., Ewen, M. E., Shirodkar, S., Arany, Z., Kaelin, W. G., and Livingston, D. M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell, 78: 161-172, 1994.
9. Xu, M., Sheppard, K. A., Peng, C. Y., Yee, A. S., and Piwnica-Worms, H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol., 14: 8420-8431, 1994.
10. Krek, W., Xu, G., and Livingston, D. M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell, 83: 1149-1158, 1995.
11. CIP1. Mol. Cell. Biol., 16: 4673-4682, 1996.
12. Adams, P. D., Sellers, W. R., Sharma, S. K., Wu, A. D., Nalin, C. M., and Kaelin, W. G. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol., 16: 6623-6633, 1996.
13. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
14. Chen, Y. N., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., and Kaelin, W. G. Selective killing of transformed cells by cyclin/cyclin-dependent kinase antagonists. Proc. Natl. Acad. Sci. USA, 96: 4325-4329, 1999.
15. Phillips, A. C., and Vousden, K. H. E2F-1 induced apoptosis. Apoptosis, 6: 173-182, 2001.
16. Wohlschlegel, J. A., Dwyer, B. T., Takeda, D. Y., and Dutta, A. Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases. Mol. Cell. Biol., 21: 4868-4874, 2001.
17. Aaronson, S. A., and Todaro, G. J. Basis for the acquisition of malignant potential by mouse cells cultivated in vitro. Science (Wash. DC), 162: 1024-1026, 1968.
18. Aaronson, S. A., and Todaro, G. J. Development of 3T3-like lines from Balb/c mouse embryo cultures: transformation susceptibility to SV40. J. Cell. Physiol., 72: 141-148, 1968.
19. Yu, Q., Geng, Y., and Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature (Lond.), 411: 1017-1021, 2001.
20. Gray, N. S., Wodicka, L., Thunnissen, A. M., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., Kim, S. H., Lockhart, D. J., and Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (Wash. DC), 281: 533-538, 1998.
21. Blagosklonny, M. V., and Pardee, A. B. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res., 61: 4301-4305, 2001.
22. Sharma, S. K., Ramsey, T. M., Chen, Y. N., Chen, W., Martin, M. S., Clune, K., Sabio, M., and Bair, K. W. Identification of E2F-1/Cyclin A antagonists. Bioorg. Med. Chem. Lett., 11: 2449-2452, 2001.
23. KIP1 cyclin-dependent-kinase inhibitor bound to the cyclin A-cdk2 complex. Nature (Lond.), 382: 325-331, 1996.
24. Brown, N. R., Noble, M. E. M., Endicott, J. A., and Johnson, L. N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol., 1: 438-443, 1999.
25. Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., and Kaelin, W. G. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (Lond.), 407: 645-648, 2000.
26. Stiewe, T., and Putzer, B. M. Role of the p53-homologue p73 in induced apoptosis. Nat. Genet., 26: 464-469, 2000.